NLRP3 and early-onset autosomal dominant Alzheimer disease: demonstrated that the nonsteroidal anti-inflammatory drugs flufenamic acid, meclofenamic acid and mefenamic acid inhibited the NLRP3 inflammasome by inhibiting volume-regulated anion channels in macrophages, and mefenamic acid ameliorated Alzheimer’s disease in a mouse model (39).